Co-Diagnostics (NASDAQ:CODX – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.02), Zacks reports. The company had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.38 million. Co-Diagnostics had a negative net margin of 563.93% and a negative return on equity of 54.94%.
Co-Diagnostics Price Performance
Shares of NASDAQ:CODX opened at $0.32 on Friday. Co-Diagnostics has a 1 year low of $0.28 and a 1 year high of $2.23. The firm has a market capitalization of $10.22 million, a PE ratio of -0.23 and a beta of 1.29. The business’s 50 day moving average price is $0.61 and its 200-day moving average price is $0.89.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright decreased their price target on shares of Co-Diagnostics from $1.50 to $1.00 and set a “neutral” rating on the stock in a research note on Friday.
About Co-Diagnostics
Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.
Featured Stories
- Five stocks we like better than Co-Diagnostics
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 03/24 – 03/28
- What is MarketRank™? How to Use it
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- What does consumer price index measure?
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
